Huntington's disease (HD) is caused by an abnormal CAG expansion in the exon 1 of huntingtin gene. The treatment of HD is an unmet medical need. Given the important role of adenosine in modulating brain activity, in this study, levels of adenosine and adenine nucleotides in the cerebral spinal fluid of patients with HD and in the brain of two mouse models of HD (R6/2 and Hdh 150Q ) were analysed. The expression and activity of ENT1 in the striatum of mice with HD were measured. Targeting adenosine tone for treating HD was examined in R6/2 mice by genetic removal of ENT1 and by giving an ENT1 inhibitor, respectively. The results showed that the adenosine homeostasis is dysregulated in the brain of patients and mice with HD. In patients, the ratio of adenosine/ATP in the cerebral spinal fluid was negatively correlated with the disease duration, and tended to have a positive correlation with independence scale and functional capacity. In comparison to controls, mRNA level of ENT1 was higher in the striatum of R6/2 and Hdh 150Q mice. Intrastriatal administration of ENT1 inhibitors increased extracellular level of adenosine in the striatum of R6/2 mice to a much higher level than controls. Chronic inhibition of ENT1 or by genetic removal of ENT1 enhanced the survival of R6/2 mice. Collectively, adenosine homeostasis and ENT1 expression are altered in HD. The inhibition of ENT1 can enhance extracellular adenosine level and be a potential therapeutic approach for treating HD.
Introduction
Huntington's disease (HD) is a dominantly inherited neurodegenerative disease characterized by progressively worsening chorea (motor dysfunction), psychiatric abnormalities and cognitive impairment (1) . It is caused by an abnormal expansion of CAG trinucleotide repeats encoding a poly-glutamine tract within the Huntingtin (HTT) protein (mutant HTT). The toxicity of HTT has been correlated with the length of polyglutamine expansion. The neuropathological features of HD include a selective loss of GABAergic medium-sized spiny neurons in the striatum and the decrease in striatal GABA levels (2) . Drugs currently available for treating patients with HD are mostly for symptomatic relief (3) . No drug is available to delay the onset or the progression of HD.
Adenosine is an important neurotransmitter that acts on four distinct adenosine receptors (A 1 , A 2A , A 2B and A 3 receptors) (4) . Among these receptors, the A 2A adenosine receptor (A 2A R) is particularly important because it is enriched in the striatum, the most vulnerable brain region in HD. Moreover, striatal neurons expressing A 2A R become dysfunctional early in HD. Stagedependent decrease of A 2A R mRNA was found in the striatum of a mouse model (R6/2) of HD before the onset of motor impairment (5) . Also, genetic removal of A 2A R in neurons worsens motor performances and survival of another mouse model (N171-82Q) of HD (6) . In this regard, the reduction of A 2A R may exacerbate neuronal degeneration in HD. On the other hand, the extracellular level of adenosine is abnormal in the brain of several rodent models of HD including R6/2, zQ175 and Tg51 (7, 8) . These findings suggest that adenosine homeostasis and the functions of adenosine receptors in the brain are aberrantly regulated in HD.
In addition to function as a neurotransmitter, adenosine also plays a critical role in cell physiology because it can be converted into adenine nucleotides (i.e., AMP, ADP, ATP) (9) . The role of adenosine in energy metabolism and neuronal activity has been implicated in various brain diseases, including epilepsy (10) and schizophrenia (11, 12) . Enhancement of extracellular adenosine level in the brain with the above-mentioned diseases is beneficial (12) (13) (14) . Consistent with this, long-term treatment with a dual-function adenosine analog (T1-11) that not only activates A 2A R but also elevates extracellular adenosine level in the brain showed beneficial effects in a mouse model (R6/2) of HD (15) .
In the brain, the extra-and intracellular levels of adenosine and adenine nucleotides are controlled by a number of proteins, including ecto-nucleotidases (CD39 and CD73) (16) , adenosine kinase (ADK), adenosine deaminase (ADA) (17) and nucleoside transporters (concentrative and equilibrative nucleoside transporters) (18, 19) . Among these proteins, equilibrative nucleoside transporters (ENTs) are facilitative transporters that mediate bidirectional transport of adenosine, depending on the adenosine gradient (18) . There are four types of equilibrative transporters (ENT1-ENT4). To date, only a few inhibitors are available for these ENTs. Nitrobenzylthioinosine (NBTI) is a selective inhibitor of ENT1, while dipyridamole (DPR) is a nonspecific inhibitor of ENT1 and ENT2 (20) . Both ENT1 and ENT2 play important roles in the transport of adenosine in the brain (21, 22) and are highly expressed in the striatum (23, 24) . Different from ENT1 and ENT2, ENT3 is expressed intracellularly and may not directly control extracellular adenosine level (25) . The role of ENT4 in the brain, which has a low affinity for adenosine at physiological pH, remains to be explored.
Given that adenosine is an important neuromodulator in the brain, the objective of this study was to investigate the regulation of brain adenosine tone in HD and to assess whether it can be a potential therapeutic target for treating HD.
Results
Adenosine homeostasis is disturbed in the brain of humans and mice with HD Given the important role of adenosine in modulating brain bioenergetics and neuronal activity, we measured the concentrations of adenosine and adenine nucleotides in the cerebrospinal fluid (CSF) of patients with HD (n ¼ 7) and control subjects (n ¼ 8). As shown in Fig. 1A , the CSF from patients with HD had a lower level of adenosine and tended to have a higher AMP level than those in controls. The concentration of ATP in the CSF of patients was inversely correlated with the number of CAG repeats (r ¼ À0.81, P ¼ 0.03; Fig. 1B ). As the number of CAG repeats is known to associate with the age of onset, a trend toward a positive correlation between ATP level and age of onset was also noted (r ¼ 0.62, P ¼ 0.14; Fig. 1C ). The ratio of adenosine/ATP in the CSF was negatively correlated with the disease duration of patients with HD (r ¼ À0.93, P ¼ 0.02; Fig. 1D ), but tended to have a positive correlation with the independence scale (r ¼ 0.76, P ¼ 0.13; Fig. 1E ) and functional capacity (r ¼ 0.60, P ¼ 0.28; Fig. 1F ). Yet, no correlation between the adenosine/ATP ratio and either CAG repeats or the age of onset was observed (data not shown). Although the number of patients is limited, these findings suggest that the homeostasis of adenosine tone is disturbed in the brain of patients with HD, which is associated with disease onset and progression.
We next evaluated the levels of adenosine and adenine nucleotides in the striatum of R6/2 mice, a widely used mouse model of HD (26) . R6/2 mice at the late disease stage (12 weeks old) and their age-matched littermate controls were evaluated. The results of in-vivo brain microdialysis study showed no difference in the extracellular levels (also defined as "interstitial fluid" (ISF)) of adenosine and adenine nucleotides between R6/2 mice and controls ( Fig. 2A) . We next evaluated the levels of adenosine and adenine nucleotides in the striatum of R6/2 mice. As shown in Fig. 2B , by analysing the striatal homogenates, the striatum of R6/2 mice had lower adenosine but higher AMP levels than the controls. Moreover, a higher AMP/ATP ratio was observed in the striatum of R6/2 mice than in the controls (Fig.  2B) . As an elevated AMP/ATP ratio can lead to the activation of AMPK, an energy sensor (27) , the above finding is consistent with previous reports that AMPK is aberrantly activated in the striatum in HD (28) (29) (30) . These data suggest that the metabolism of adenosine and adenine nucleotides is aberrantly regulated in the striatum of R6/2 mice.
The expression of ENT1 and ENT2 in the striatum is increased in two mouse models of HD (R6/2 and Hdh (CAG)150 )
To further characterize the regulation of adenosine metabolism in the striatum of mice with HD, we assessed the gene expression of several major proteins (including ENT1, ENT2, ADK, ADA, CD39 and CD73) that modulate the amount of adenosine by RT-qPCR. Our results showed that R6/2 mice at the late disease stage (12 weeks old) had higher levels of ENT1, ENT2 and ADK in the striatum than their littermate controls (Fig. 3A) . No difference in the expression of ADA, CD39, or CD73 was detected. We also measured the transcript levels of A 2A R and enkephalin (ENK) as markers for striatal degeneration (28, 31) . As shown in Fig. 3A , the amounts of A 2A R and ENK in the striatum of R6/2 at the age of 12 weeks were markedly lower than their littermate controls. We next determined the expression of those genes involved in the adenosine homeostasis in the striatum of a knockin mouse model (Hdh (CAG)150 ). This mouse model harbours a fulllength mutant HTT with a pathogenic polyQ tract of 150 repeats, and exhibits neurological symptoms at the age of 16 months (32) . Similar to the findings in R6/2 mice, when compared with their littermate controls, higher levels of ENT1 and ENT2 transcripts were observed in the striatum of Hdh (CAG) HD. We also performed experiments to determine the expression of ENT1 and ENT2 in the striatum of R6/2 mice at the age of 4, 7 and 12 weeks. Interestingly, the up-regulation of ENT1 and ENT2 in the striatum of R6/2 mice appeared to be dependent of disease stage ( Fig. 3C and D) .
The activities of ENT1 and ENT2 are enhanced in the striatum of R6/2 mice with HD
To assess whether the activities of ENT1 and ENT2 were also altered in the striatum of mice with HD, a selective ENT1 inhibitor (NBTI) and a non-selective inhibitor for both ENT1 and ENT2 (DPR) were employed using in-vivo brain microdialysis assay in awake freely moving R6/2 mice. Intrastriatal perfusion of NBTI (10 lM) produced a marked increase in the extracellular adenosine level in the striatum of R6/2 mice (12 weeks old), while only a moderate increase was observed in their littermate controls ( Fig. 4A and B). Co-administration of NBTI (10 mM) and DPR (10 mM) resulted in a prolonged increase in the extracellular adenosine level in the striatum of R6/2 mice ( Fig. 4C and D). These findings suggest that the activities of ENT1 and ENT2 are enhanced in the striatum of R6/2 mice.
Genetic removal of ENT1 enhances the survival of mice with HD (R6/2)
ENT1 and ENT2 are the important nucleoside transporters that regulate intra-and extracellular levels of adenosine (18), whose expression and activities are both up-regulated in mice with HD (Figs. 3 and 4). We are particularly interested in ENT1 because the functions of ENT1 and A 2A R appear to be inter-correlated (33) and that ENT1-specific inhibitors (e.g., NBTI) are available. Conversely, no ENT2-specific inhibitor is currently available, which inevitably hinders the investigation of the physiological function of ENT2 in vivo. To evaluate the concept of using ENT1 as a target to treat HD, we crossed R6/2 mice with ENT1-knockout mice. The resultant mice that contained one copy of mutant htt and no ENT1 were designated R6/2-ENT . Surprisingly, when brain adenosine tone was evaluated, both extracellular and striatal levels of adenosine were comparable between R6/2-ENT1 þ/þ and R6/2-ENT1 -/-mice (Fig. 5D ). 
Pharmacological suppression of ENT1 enhances the survival and improves motor function of mice with HD (R6/2)
To further assess whether elevation in striatal adenosine tone is beneficial in HD, we chronically suppressed ENT1 in R6/2 mice using JMF1907, an adenosine analogue that inhibits ENT1 with a low affinity. At a concentration of 18-fold of its Ki value toward ENT1 inhibition (3.47 lM) (34), JMF1907 inhibited about 80% of adenosine uptake by PC12 cells that express endogenous ENT1, comparable to the inhibition caused by 100 nM NBTI (118-fold of its Ki value of 0.85 nM) (Fig. 6A ). We selected JMF1907, but not NBTI, for the following in-vivo experiment because of its ability to enter the brain. A single intraperitoneal injection of JMF1907 (20 mg/kg) resulted in submicromolar concentrations of JMF1907 in the brain (Fig. 6B ). In addition, a single intraperitoneal injection of JMF1907 increased extracellular level of adenosine in the striatum of wild-type mice, but not in that of ENT1 knockout mice (Fig. 6C) , indicating JMF1907 enhances extracellular adenosine level in vivo through the inhibition of ENT1.
In R6/2 mice, consistent with the above findings, the administration of JMF1907 enhanced the extracellular adenosine level in the striatum (Fig. 6D) . However, JMF1907 treatment did not change the intracellular adenosine level in the striatum (data not shown), confirming that JMF1907 mainly targets at ENT1. Chronic treatment of JMF1907 using ALZET osmotic minipumps (0.11 mg/kg/ day, subcutaneous administration) from the age of 7 weeks counteracted the progressive deterioration in motor coordination as assessed by rotarod performance (Fig. 6E) . No effect of JMF1907 on body weight was observed (Fig. 6F) . Of note, the shorten lifespan of R6/2 mice was also enhanced by chronic treatment with JMF1907 by 5.7% (the mean survival time of JMF1907-treated and control R6/ 2 mice were 112.4 6 1.4 days and 106.3 6 1.5 days, respectively, P ¼ 0.03, Fig. 6G ). These results suggest that targeting ENT1 inhibition is a potential therapeutic approach for treating HD.
Discussion
In spite of extensive efforts, therapeutic treatment to delay the progression of HD is not yet available. Nevertheless, several Figure 4 . The function of ENT1 is changed in the striatum of mice with Huntington's disease (R6/2). The extracellular adenosine levels in the striatum of R6/2 mice (n ¼ 5-6; white circles) and their littermate controls (WT, n ¼ 3-5; black circles) before and after the intracranial infusion of NBTI (10 lM; A and B) or NBTI plus DPR (both at 10 lM; C and D). The mean adenosine levels of baseline and dosing period were quantified at right panels (B and D, respectively). Baseline concentrations were calculated as the mean value of pre-dosing period. The mean value of each dosing period was calculated at indicated time intervals (0-1 h and 1-5 h). Data are presented as mean 6 SEM. (*P < 0.05 or **P < 0.01 compared to WT; a P < 0.05 compared to baseline).
earlier studies have reported that extracellular adenosine level in the brain of mice with HD was abnormally regulated during disease progression (7, 8) , suggesting that the machinery that controls both intracellular and extracellular adenosine homeostasis in the brain is likely to be altered in HD. In this study, we present evidences to demonstrate that adenosine homeostasis in the brain of humans and mice with HD was changed (Figs. 1, 2 and 4). This abnormality may be, at least in part, caused by the elevation of two major adenosine transporters (ENT1 and ENT2; Figs. 3 and 4) . Such up-regulation of ENT1 and ENT2 exists in two different mouse models with HD (R6/2 and Hdh (CAG)150 ; Fig. 3 ) and is disease-stage dependent ( Fig. 3C and D) . Our findings are consistent with a recent study that showed a dynamic regulation of ENT1 transcripts during the progression of HD based on a microarray analysis of more than 100 human subjects (8) . Most importantly, pharmacological and genetic suppression of ENT1 both produced beneficial effects on the survival of a mouse model of HD (R6/2, Figs. 5 and 6), supporting that ENT1 is a potential drug target for HD.
In the pilot study of CSF from human subjects (Fig. 1) , we found that the average of adenosine level in the CSF of patients with HD was lower than that of control subjects (Fig. 1A) . It was also noted that the concentration of adenosine, when normalized with that of ATP, was inversely correlated with disease duration (Fig. 1D ) and tended to positively correlate with independence scale and functional capacity ( Fig. 1E and F ; measured by the UHDRS) that mainly reflect motor function. Although the sample size is small, these findings indicate that adenosine level in the CSF may serve as a biomarker for HD. On the other hand, the level of ATP in the CSF was negatively correlated with the CAG repeats (Fig. 1B) and tended to associate with the age of onset (Fig. 1C) . Since ATP and its metabolites are associated with energy homeostasis in the brain, this finding may reflect the energy depletion caused by mitochondrial dysfunctions in patients with longer repeats (35) . Nevertheless, further studies with large cohorts need to be conducted to thoroughly assess the association between the levels of adenosine and adenine nucleotides in the CSF and the clinical features of patients with HD.
While the level of adenosine was lower in the CSF of HD patients than in controls, its extracellular level (or IFS, measured by in-vivo brain microdialysis) in the striatum of R6/2 mice was not. Given that CSF is mainly secreted by the chroid plexus and is distributed through the ventricular systems, the concentrations of a molecule in the CSF and ISF (the intercellular space being dialyzed by the microdialysis probe) are not necessarily correlated (36) . The level of adenosine in the ISF of the brain is tightly controlled locally by a set of proteins including CD39, CD73, ADA, ADK and adenosine transporters during pathological conditions (37) . The well-controlled adenosine homeostasis can be disease-stage dependent as suggested recently (8), and may explain the seemingly contradictory findings in rodent mouse models. Specifically, the striatal adenosine tone in two rodent models of HD (zQ175 and Tg51) was lower than their littermate controls at an early disease stage when motor dysfunction started to show up (38, 39) . Conversely, another HD mouse model (R6/2) showed a slightly higher (7) or a trend of increase ( Fig. 2A) in their striatal adenosine tone than their littermate controls at the symptomatic and the late disease stages, when motor impairment progressively become more severe. This apparent biphasic regulation of adenosine tone in rodent models of HD might result from a compensatory effect during disease progression. An earlier study suggests that inflammation leads to an enhancement of astrocyte-derived adenosine release in the brain (40) . Inflammation may also lead to an increase in the expression of ENT1 and ENT2 (41) . Because an abnormally higher neuroinflammatory response was reported in the brain of HD mice at the late disease stage (42), it is possible that (for E-G, *P < 0.05, **P < 0.01 and ***P < 0.001 represent the statistically significant differences between WT-CON and R6/2-CON; # P < 0.05 indicates the statistic difference between adenosine tone might be elevated during disease progression via an inflammation-dependent manner. Also, regulation of proteins involved in adenosine homeostasis during disease progression may contribute to the regulation of adenosine tone in the striatum. For example, R6/2 mice have a higher transcript level of ADK in the striatum than their littermate controls at the late disease stage (Fig. 3A) . In addition, their ADK activity was also higher than that of control mice (R6/2, 2.56 6 0.26 mmol/g/ min; WT, 1.83 6 0.07 mmol/g/min; Mean 6 SEM, P ¼ 0.02, n ¼ 6 for each group). Such higher expression and activity of ADK in R6/2 mice are expected to facilitate the intracellular conversion of adenosine to AMP or inosine, which reduces the intracellular adenosine level (Fig. 2B ) and may subsequently contribute to the reduction of extracellular adenosine level via an ENT1/ ENT2-dependent pathway. Further investigation of those enzymes that control the metabolism and conversion of adenosine and adenine nucleotides during disease progression of HD in rodent models are needed to clarify how adenosine homeostasis is regulated and by which enzyme(s) in HD.
Results from a recent report (8) and in the present study ( Figs 3 and 4) suggest that both the expression and function of ENT1 are enhanced in humans and mice with HD. The potential role of ENT1 as a therapeutic target for HD has been suggested earlier (8, 15) . Consistent with this hypothesis, inhibition of the ENT1-mediated adenosine transport in vivo by either knockout of the ENT1 gene or employing a low-affinity ENT1 inhibitor (i.e., JMF1907) improved the shorten lifespan of R6/2 mice (Figs 5C and 6F). As cardiac dysfunction is one of the causes of death in HD (43) , this may be due to cardioprotection by the elevated circulating adenosine level in mice with genetic removal or inhibition of ENT1 (44, 45) . Intriguingly, the amelioration of the motor impairment as assessed by rotarod performance was only observed in R6/2 mice chronically treated with JMF1907 (Fig. 6D ), but not in R6/2-ENT -/-mice (Fig. 5A ). This discrepancy might be related to the distinct effect of genetic removal and pharmacological inhibition of ENT1 on the striatal extracellular adenosine level in R6/2 mice ( Figs 5D and 6C ). The inability of genetic removal of ENT1 to raise the striatal adenosine level might be due to the compensatory effect among proteins/enzymes that control adenosine homeostasis. Consistent with this hypothesis, the expression of ADA, but not other components (ENT2, CD39, CD73 and ADK) tested, was higher than their littermate controls in the striatum of ENT1-knockout mice (relative ADA mRNA expression, R6/2, 150% 6 11%; WT, 100% 6 5%; Mean 6 SEM, P ¼ 0.01, n ¼ 3 for each group). This higher amount of ADA is expected to rapidly degrade adenosine and may explain why genetic removal of ENT1 failed to elevate extracellular adenosine tone (Fig. 5D) . On the contrary, the blood-brain barrier-permeable low-affinity inhibitor of ENT1 (JMF1907) effectively raised the extracellular level of adenosine in vivo (Fig.  6D ). This effect on adenosine tone is important because previous studies suggest that maintaining a proper adenosine tone in the brain is important for the neuroprotective function of A 2A R under various pathophysiological conditions (46) , and is required for the function of a critical neurotrophic factor (brainderived neurotrophic factor) in HD (47) . Also, motor function in mice with HDs can be improved by the activation of A 2A R (15, 28) , but worsened by genetic removal of A 2A R (6) . Thus, the enhanced extracellular adenosine level in the stratum caused by JMF1907 treatment, but not by genetic knockout of ENT1 (Fig.  5D ), may potentiate A 2A R activation and mediate the beneficial effect on motor deterioration. Nevertheless, it should be pointed out that JMF1907 is also a dual-function adenosine compound that not only inhibits ENT1, but also activates A 2A R with a low affinity (Ki value ¼ 4.39 lM) (15) . These multi-function adenosine compounds (such as JMF1907 and T1-11), which are capable of simultaneously enhancing adenosine tone and activating A 2A R, are likely to produce synergistic beneficial effects on HD, as shown in the present study and reported earlier (15) . In addition to ENT1, ENT2 was also up-regulated in HD (Fig. 3) . Blockage of ENT2 during disease progression should be able to further enhance adenosine tone and thus sustain neuronal survival. However, unlike ENT1 whose function has been better investigated using specific inhibitors and a genetically modified mouse model (ENT1-KO), information regarding ENT2 is scarce. Because ENT2 has a low affinity and a high capacity for adenosine transport, it is postulated that ENT2 is predominant when the adenosine level is greatly increased (21) . Given that the inhibition of ENT2 provided a sustained increase in the extracellular adenosine level (Fig. 4C) , further development of selective ENT2 inhibitors that can pass across the blood-brain barrier is worth an attention.
The mechanism underlying the up-regulation of ENT1 and ENT2 in the striatum of HD mice is currently unknown. In addition to the potential role of inflammation on ENT expression as described above (41), it is interesting to note that mutant HTT has been shown to directly or indirectly disturb the transcription machinery and subsequently alter the expression of a wide variety of genes (including neurotrophic factors, receptors and transporters) (48) (49) (50) . For example, both mutant HTT and normal HTT directly interact with DNA-binding proteins, and alter gene expression (48) . Changes in DNA methylation evoked by mutant HTT are also associated with gene expression (51) . Considering that mutant HTT may serve as an upstream regulator at the transcriptional or epigenetic level to regulate gene expression, it is possible that the expression of mutant HTT may directly or indirectly causes the up-regulation of ENT1 and ENT2 in the striatum of HD mice. Moreover, abnormal intracellular adenosine hemostasis might also impact on the expression or/and function of ENT1 and ENT2 through a compensatory pathway. In order to maintain a proper intracellular adenosine level, the enhanced expression and function of ADK in the striatum of R6/2 mice, as we have observed herein, might cause the enhanced functions of ENT1 and ENT2 (Fig. 4A and C) . These intriguing observations certainly warrant further investigation in the future.
In summary, our results demonstrate that adenosine homeostasis is abnormally altered in the striatum in humans and mice with HD. Blockage of ENT1 using either pharmacological or genetic approaches both improved the survival of mice with HD. An increase of extracellular adenosine level may provide beneficial effects to improve motor function. Strategies aimed at blockage of ENT1 and the increase of adenosine tone in the brain may prove to be useful for the treatment of HD. 
Materials and Methods

Collection of human cerebrospinal fluid (CSF)
Samples of CSF were collected from seven patients (six males, one female) with HD and eight controls (three males, five females; Table 1 ) who were recruited from a neurological clinic of Chang Gung Memorial Hospital, and were genetically diagnosed. The Unified Huntington's Disease Rating Scale (UHDRS) of each patient was assessed by clinicians (Dr. Yih-Ru Wu and Dr. Chiung-Mei Chen) before the CSF were collected. The controls were patients who were admitted due to migraine, tension headache, spontaneous intracranial hypotension, or degenerative spine diseases. All these controls had no systemic infection (chronic renal, cardiac or liver dysfunction), autoimmune diseases, or malignancies. The CSF samples were immediately examined for the absence of inflammation (no pleocytosis), and were then centrifuged at 4,500 Â g for 30 min to eliminate cells and other insoluble material, aliquoted and stored at À80 C until analysis. The CSF study was performed under a protocol approved by the Institutional Review Boards of Chang Gung Memorial Hospital and all examinations were performed after obtaining written informed consents.
In-vivo brain microdialysis
Mice were anaesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg) intraperitoneally and were fixed on a stereotaxic instrument (Stoelting, Wood Dale, IL, USA). A vertical guide cannula was stereotaxically implanted into the right side of the striatum at the following coordinates: A-P þ0.6 mm and M-L À1.2 mm from the bregma and D-V -2.5 mm below the dura according to the stereotaxic atlas of Paxinos et al. (52) . Twenty-four hours after the implantation of guide cannula, a microdialysis probe (MAB 10.8.2.Cu, Microbiotech/se AB, Stockholm, Swedish) was inserted into the mouse brain through the guide cannula. Mice were kept in a cage with a 6-hour stabilization period before the collection of dialysis samples. Only probes with a relative recovery greater than 10% were used. For the administrations of ENT1 inhibitors, NBTI (10 lM) or NBTI plus DPR (both at 10 mM) were prepared in 2% dimethyl sulfoxide in Ringer's solution (RS; 2.3 mM CaCl 2 , 4 mM KCl and 147 mM NaCl) and were infused to the striatum through the dialysis probe. JMF1907 [20 mg/kg; dissolved in 10% dimethyl sulfoxide in normal saline (0.90% w/v of NaCl)] was given to mice by an intraperitoneal injection. The microdialysis probe was perfused with RS at a flow rate of 1.0 ml/ min, and brain dialysate was collected every 30 min. The samples were frozen at À20 C until assayed.
Brain extraction
The striatum of each mouse was rapidly dissected and transferred to an Eppendorf chilled in liquid nitrogen. The frozen tissues were homogenized with 85 ll of ice-cold 0.6 N perchloric acid and were centrifuged at 11,000 Â g for 30 min at 4 C. An aliquot of 80 ll of the supernatant was neutralized with 16 ll of 2 M K 2 CO 3 , vortexed for 30 sec, and then centrifuged at 11,000 Â g for 10 min. The upper aqueous layer was collected and stored at À80 C until derivatization.
Nucleotide derivatization and HPLC analysis
Adenosine and adenine nucleotides were converted to the fluorescent 1, N 6 -etheno-adenine derivatives as described by Bhatt et al. (53) . A 25 lL aliquot of each sample was mixed with 75 ll of reaction reagent that was freshly prepared by mixing 7.8 M chloroacetaldehyde and 1 M acetate buffer (pH 4.5) (11.2:138.8 by volume). After being centrifuged at 500 Â g for 2 min at room temperature (RT), samples were heated at 60 C for 60 min, then immediately placed on ice to stop the reaction, and centrifuged at 500 Â g for 2 min. An aliquot of 85 ll of the supernatant was injected to a HPLC system (Hitachi, Tokyo, Japan). The separation of analytes was performed on a COSMOSIL 5C18-AR-II column (5 lm, 250 Â 4.6 mm, Nacalai Tesque, Inc., Kyoto, Japan) equipped with a C18 SecurityGuard cartridge (Phenomenex, Torrance, CA, USA). The mobile phase was consisted of buffer A (30 mM KH 2 PO 4 and 0.8 mM TBAB, pH 5.45) and The derivatized adenosine and adenine nucleotides were eluted off the column at a flow rate of 1 ml/min by a mobile phase with a gradient manner. The gradient was initiated from a composition of 80% buffer A and 20% buffer B for 5 min, increased to 50% of buffers A and B over a 4-min period and held constant for 10 min, then decreased to a composition of 80% buffer A and 20% buffer B over a 4-min period and held constant for 5 min until the end of the run. The re-equilibration time between samples was 20 min. The etheno-derivatives were detected by a fluorescence detector (L2200, Hitachi, Tokyo, Japan) using an excitation wavelength of 280 nm and an emission wavelength of 410 nm.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from each sample by the acid phenolguanidinium-chloroform method using the TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer's instructions. First-strand cDNA was synthesized from total RNA (1,000 ng) using an oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and the GoScriptTM reverse transcription system (Promega, WI, USA) according to the manufacturer's instruction. The cDNA (1 ll) was mixed with 7 ll of DEPC-treated sterile deionized distilled water, 10 ll of Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK), and forward and reverse primers at a final concentration of 0.5 lM each. The primer sequences were listed in Table 2 . The relative mRNA amount of the target gene was normalized to that of a reference gene (beta-actin). Waltham, MA, USA) was added to initiate adenosine uptake by PC12 cells at 37 C. The reaction was terminated by placing cells on ice. After extensive washes using ice-cold KRH buffer, PC12 cells were solubilized using the SOLVABLE TM solution (PerkinElmer). Cell lysates were collected for radioactivity counting. Cells treated with excess amount of adenosine (100 lM) were used to examine the non-specific adenosine uptake.
Rotarod performance
A rotarod apparatus (UGO BASILE, Comerio, Italy) was used to evaluate motor coordination of mice at a constant speed (12 rpm) over a period of 2 min (54). All mice were pre-trained to run on the rotarod apparatus at the age of 6 weeks. The rotarod performance of each mouse was determined three times per week from the age of 8-12 weeks. For each test, mice were placed on the standing apparatus before the initiation of rolling, and the latency to fall was recorded and analysed.
Statistical analysis
Comparisons of mRNA levels, adenosine concentrations and adenine nucleotide concentrations between HD and control groups were made by unpaired t test and one-way ANOVA. Data of rotarod performance and body weight change among groups were assessed by two-way ANOVA with uncorrected Fisher's LSD test. Survival data were analysed by the Mantel-Cox logrank test and Kaplan-Meier survival curves. Unless otherwise indicated, a level of significance of 0.05 was considered statistically significant. 
